Interchange Capital Partners LLC Buys 5,432 Shares of Merck & Co., Inc. $MRK

Interchange Capital Partners LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 51.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,005 shares of the company’s stock after buying an additional 5,432 shares during the period. Interchange Capital Partners LLC’s holdings in Merck & Co., Inc. were worth $2,057,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its position in shares of Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after acquiring an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC lifted its position in Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after acquiring an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC lifted its position in Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after acquiring an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Merck & Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after purchasing an additional 359,356 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 11,699 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares of the company’s stock, valued at $4,942,755. This trade represents a 21.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last ninety days. 0.17% of the stock is owned by corporate insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades and higher valuations: Daiwa Securities upgraded Merck to “outperform” with a $143 price target, while other analyst commentary placed fair-value estimates in the $140–$155 range. A separate valuation assessment raised fair value from $132.78 to $136.85, citing pipeline progress and recent business-development activity. Merck fair value article
• Positive Sentiment: Shares reached a record level: Merck was among the companies touching fresh all-time highs, signaling strong recent momentum and investor confidence in its earnings outlook. Merck all-time high article
• Positive Sentiment: Pipeline and core products support growth: Analysts highlighted Merck’s late-stage pipeline, business-development efforts and continued demand for Keytruda. Recent quarterly results also showed revenue of $16.61 billion, above expectations, with oncology and Animal Health cited as important contributors. Merck earnings call analysis
• Neutral Sentiment: Dividend provides income support: Merck declared a quarterly dividend of $0.85 per share, or $3.40 annualized. The payout may support demand for the stock, although the reported payout ratio is elevated.
• Negative Sentiment: Cluster of executive sales: Several executives sold shares, including Jennifer Zachary’s approximately $10.7 million sale, Chirfi Guindo’s $1.35 million sale and Richard Deluca’s additional $1.54 million sale. These transactions reduced their holdings substantially and could weigh modestly on sentiment, though insiders retained shares.
• Negative Sentiment: Keytruda concentration risk: Keytruda remains Merck’s main growth engine, but future patent loss and increasing competition could pressure sales and earnings. Investors will look for newer products and pipeline candidates to offset that risk. Keytruda growth outlook article

Merck & Co., Inc. Trading Up 2.0%

Shares of MRK stock opened at $135.57 on Friday. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.68. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a 50-day simple moving average of $125.25 and a two-hundred day simple moving average of $119.83. The company has a market capitalization of $334.49 billion, a price-to-earnings ratio of 108.46, a PEG ratio of 5.73 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter last year, the firm earned $2.13 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts anticipate that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Analyst Ratings Changes

A number of brokerages have commented on MRK. Bank of America boosted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. BMO Capital Markets lifted their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Barclays upped their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, Scotiabank increased their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Fifteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $135.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.